摘要
内分泌治疗是激素受体阳性乳腺癌的主要治疗手段。随着一些重要临床试验证据的出现,内分泌治疗的策略也不断得到更新,包括早期乳腺癌辅助内分泌治疗的延长,卵巢功能抑制的联合应用等,进一步改善了患者的生存。内分泌耐药机制研究的不断深入也为晚期乳腺癌的内分泌治疗提供了新的治疗手段,随着新的药物被开发,包括雌激素受体下调剂、内分泌联合靶向治疗药物的应用,明显改善了患者的预后,显示出良好的临床应用前景。
Endocrine therapy is the mainstay treatment for hormone-receptor-positive breast cancer. Based on new evidences collected from clinical trials, new strategies have been available and have improved the long-term outcomes of patients, including longer endocrine treatment of early breast cancer, combined use of ovarian suppression, and so on. In parallel with expanding knowledge about the resistance mechanisms to endocrine therapy, new agents for hormone receptor-positive metastatic breast cancer continue to appear. The selective estrogen-receptor degrader, fulvestrant, and new endocrine-target combinations provide significant and clinically meaningful improvements in outcomes. This review will explore the current and investigational approaches to endocrine therapy for hormone-receptor-positive breast cancer.
出处
《山东大学学报（医学版）》
CAS
北大核心
2018年第1期27-31,共5页
Journal of Shandong University:Health Sciences
基金
陕西省国际科技合作与交流计划项目(2016KW-010)
国家自然科学基金(81572917)
关键词
乳腺癌
激素受体阳性
内分泌治疗
靶向治疗
预后
Breast cancer
Hormone receptor positive
Endocrine therapy
Target therapy
Prognosis
